|
To enter a Simulation, please read and scroll through the information below and click the acceptance button at the bottom of the page.
Regaining Control of Severe Asthma
Cases Developed by Expert Faculty
Harold S. Nelson, MD
Professor of Medicine, National Jewish Health
Professor of Medicine, University of Colorado Health Sciences Center
Stanley J. Szefler, MD
Director of Clinical Pharmacology, National Jewish Health
Professor of Pediatrics and Pharmacology, University of Colorado Health Sciences Center
Release Date
March 6, 2009 and is valid for 1 year.
Requests for credit must be received no later than March 6, 2010.
Introduction
Asthma is a chronic, respiratory illness that affects an estimated 16.1 million individuals in the United States, 7.3% of the population. The morbidity and mortality from asthma results in a significant and increasing burden to the healthcare system. The economic costs of the disease are significant, estimated at $19.7 billion in direct and indirect costs each year.
Although evidence-based guidelines exist for asthma diagnosis and management, adherence to these guidelines is suboptimal, contributing to substantial variation in asthma outcomes.
Target Audience
This activity was developed for Pulmonologists, Allergists, Nurse Practitioners, and Physician Assistants who have interest in this area.
Learning Objectives
Following completion of this series of case simulations, participants should be able to:
- Describe changes to national guidelines for the diagnosis and management of treatment as reflected in the EPR-3.
- Identify barriers to implementing the EPR-3 guidelines in their office and steps they can take to overcome those barriers.
- Use non-invasive tests to correctly identify the severity of their patients’ asthma and their level of control.
- List recommendations from the EPR-3 guidelines for managing patients with severe asthma.
- State the indications for the use of leukotriene antagonists, zileuton, LABAs, and anti-IgE monoclonal antibody therapy in patients with asthma.
- List the steps required to identify potential responders to anti-IgE therapy.
Accreditation Statement
National Jewish Health is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.
Designation Statement
National Jewish Health designates this educational activity for a maximum of 2 AMA PRA Category 1 Credits™. Physicians should only claim credit commensurate with the extent of their participation in the activity.
This CME Activity is sponsored by National Jewish Health.
This program was made possible by educational grants from Genentech and Novartis and from AstraZeneca.
Disclosure Information Listed for CME Content Development and Approval Committee and Participating Program Faculty
In accordance with the Accreditation Council for Continuing Medical Education, National Jewish Health requires that all program faculty, content developers, CME approval committee, and medical writers in a position to control the content of this activity are expected to disclose any or not significant financial interest or other relationship with any proprietary entity producing health care goods or services, with the exemption of non-profit or governmental organizations and non-health care related companies. Our goal is to ensure that there is no compromise of the ethical relationship that exists between those in a position to control the content of the activity and those attending the activity and their respective professional duties.
Significant financial interest is defined as receiving, or in the past twelve months having received, a salary, royalty, intellectual property rights, consulting fee, honoraria, ownership interest (e.g., stocks, stock options or other ownership interest, excluding diversified mutual funds), or other financial benefit. Financial benefits are usually associated with roles such as employment, management position, independent contractor (including contracted research), consulting, speaking and teaching, membership on advisory committees or review panels, board membership, and other activities from which remuneration is received or expected.
All CME Educational Activities sponsored by National Jewish Health are reviewed by our faculty CME committee to ensure a balanced and evidence-based presentation. Any potential conflict of interest among program faculty has been identified and resolved according to ACCME guidelines.
Faculty Disclosures
In accordance with the Accreditation Council for Continuing Medical Education, National Jewish Health requires that all persons in a position to control the content of a CME activity, including the CME review committee disclose all significant financial interest with commercial interests.
Key
A - Advisory Board B - Board of Directors C- Consultant E- Employer
F - Founder I - Investigator O - Other SP- Speaker SH - Stockholder
Stephen K. Frankel, MD
I – Actelion, BioCryst, Genzyme, Gilead, Intermune, NHLBI, Novartis
SH – Teva
Harold S. Nelson, MD
C – Abbott, AstraZeneca, Boehringer-Ingelheim,
Dey, L.P., Dynavax Technologies, Dyson, Genentech, GlaxoSmithKline, Johnson & Johnson, MediciNova, Novartis, Schering- Plough, Sepracor, Teva
I – Altana, AstraZeneca, Boehringer-Ingelheim, Ception, Genentech, Novartis, Schering-Plough, Sepracor, Wyeth
SP – AstraZeneca , GlaxoSmithKline
Michael Schwartz, MD
Has no significant financial interest to report
Stanley J. Szefler, MD
A – Genentech, GlaxoSmithKline, Merck, Novartis
I – GlaxoSmithKline
SP – Merck
Disclaimer
The information provided during this CME activity is for continuing education purposes only and is not meant to substitute for the independent medical judgment of a physician relative to diagnostic and treatment options of a specific patient's medical condition.
Hardware/Software Requirements
The simulation requires version 4.x browsers or higher from Microsoft or Netscape or Mozilla FireFox version 1.5.x or higher. Certain activities may require additional software to view multimedia, presentation or printable versions of their content. There are no specific hardware requirements.
I have read the CME information above.
|
